Globus Medical
Builds spine and orthopedic systems spanning implants, robotics, navigation, and pain therapies.
Something off on this page? Send us feedback.
Profile
Develops spine and orthopedic implants, robotic navigation, imaging, surgical planning, neuromonitoring, and chronic-pain therapies. Operates globally through Musculoskeletal Solutions and Enabling Technologies within one reportable segment, with growth shaped by repeated product launches and acquired portfolios.
Develops musculoskeletal products and enabling technologies for spine, orthopedic trauma, joint reconstruction, biologics, and chronic pain. The Excelsius ecosystem combines surgical planning, imaging, navigation, and robotics, while intraoperative neuromonitoring adds a service component.
Operates globally as one reportable segment, selling through direct representatives and distributors. An engineering-led model centered on surgeon feedback, repeated product launches, and selective acquisitions has broadened a spine-focused franchise through the NuVasive and Nevro combinations.
Execution depends on surgeon and hospital adoption, regulatory clearances, quality-system compliance, acquired-business integration, intellectual-property protection, and reliable direct and distributor channels. Whether the FDA warning letter concerning ExcelsiusGPS quality systems and medical-device reporting has been closed is not publicly confirmed.
Company facts
Categories
Key statistics
Year to date −5.0% · Average volume (30d) 1.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 28, 2026 | UBS | Initiate | Neutral | $82 | ||
| Jul 16, 2026 | Truist Financial | Target | $115 | $100 | ||
| Jul 13, 2026 | RBC Capital | Reiterate | Outperform | $100 | $115 | |
| Jul 8, 2026 | BMO Capital | Initiate | Outperform | $94 | ||
| Jul 8, 2026 | Stifel Nicolaus | Target | $64 | $80 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | $1.10 | $1.34 | +21.8% | $782.9M | $789.6M | +0.9% | +1.57% |
| May 7, 2026Q1 FY26 | $0.92 | $1.12 | +21.7% | $740.3M | $759.9M | +2.6% | −8.37% |
| Feb 24, 2026Q4 FY25 | $1.06 | $1.28 | +20.8% | $801.7M | $826.4M | +3.1% | +4.72% |
| Nov 6, 2025Q3 FY25 | $0.78 | $1.18 | +51.1% | $734.7M | $769.0M | +4.7% | +35.94% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $598.1M | $745.3M | $769.0M | $826.4M | $759.9M | $789.6M | |
| Gross profit | $402.7M | $496.6M | $486.7M | $595.1M | $525.8M | $548.2M | |
| Operating income | $97.0M | $76.1M | $135.0M | $171.7M | $163.6M | $182.4M | |
| Net income | $75.5M | $202.8M | $119.0M | $140.6M | $124.3M | $151.6M | |
| Diluted EPS | $0.54 | $1.49 | $0.88 | $1.01 | $0.90 | $1.10 | |
| Gross margin | 67.3% | 66.6% | 63.3% | 72.0% | 69.2% | 69.4% | |
| Operating margin | 16.2% | 10.2% | 17.6% | 20.8% | 21.5% | 23.1% |
Fiscal years (4-quarter sums)FY21 $958.1M · FY22 $1.02B · FY23 $1.57B · FY24 $2.52B · FY25 $2.94B
Revenue by product · FY24
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $595.1M · Total debt $111.2M · Total assets $5.49B · Shareholders' equity $4.77B
Dividends
No dividends on record.
Ownership
Shares outstanding 134.86M · Float 133.90M · 99.3% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.81M | 8.01% | 13F | Aug 7, 2026 |
| Jupiter Topco LLC | 8.20M | 6.08% | 13F | Aug 14, 2026 |
| Janus Henderson Group PLC | 7.03M | 6.10% | 13G | May 14, 2025 |
| Vanguard Capital Management LLC | 5.11M | 3.79% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 4.99M | 3.70% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 18, 2026 | Stephen T. Zarrilli | director | −25,000 | $87.04 |
| Jun 5, 2026 | David D. Davidar | director | −25,000 | $80.76 |
| Feb 25, 2026 | Kelly Huller | officer: EVP, GC, Corporate Secretary | −20,000 | $94.50 |
| Feb 12, 2026 | Kelly Huller | officer: EVP, GC, Corporate Secretary | −10,000 | $87.67 |
| Jan 8, 2026 | Leslie V. Norwalk | director | −2,000 | $101.10 |
Peers
- Medtronic
Spine, surgical-enablement, and pain-stimulation rival
- Johnson & Johnson
Orthopaedics rival across spine, robotics, trauma, and joints
- Stryker
Spine robotics, joint reconstruction, and trauma overlap
- Alphatec
Spine-focused rival in implants, imaging, monitoring, and navigation
- Zimmer Biomet
Joint-reconstruction, robotics, and trauma/extremities competitor
- Smith & Nephew (ADR)
Hip/knee reconstruction, robotics, and trauma overlap
- Orthofix Medical
Spine, biologics, navigation, and limb-reconstruction rival
- Boston Scientific
Spinal-cord-stimulation rival in chronic pain neuromodulation
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Globus Medical | $85.02 | +2.47% | $11.19B | 21.3 | 16.2 | 3.6 | +5.9% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| Stryker | $334.18 | +1.06% | $126.77B | 34.3 | 20.6 | 4.9 | +9.4% |
| Alphatec | $9.44 | +0.16% | $1.45B | — | 18.7 | 1.8 | +15.1% |
| Zimmer Biomet | $100.91 | −0.00% | $19.52B | 24.6 | 11.5 | 2.3 | +4.8% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Orthofix Medical | $9.70 | 0.00% | $392.1M | — | — | 0.5 | +3.9% |
| Boston Scientific | $46.85 | +0.03% | $69.62B | 19.0 | 14.2 | 3.3 | +7.5% |
| Median | 24.5 | 17.0 | 2.8 | +7.1% |